Effects of lipid-lowering treatment on platelet reactivity and platelet–leukocyte aggregation in diabetic patients without and with chronic kidney disease: a randomized trial
Nephrology Dialysis Transplantation, 06/15/2012Almquist T et al.
Diabetes mellitus (DM) patients with chronic kidney disease (CKD) stages 3–4 had increased platelet–leukocyte aggregation (PLA) and inflammatory activity compared with DM patients with normal glomerular filtration rate. Simvastatin + ezetimbe decreased PLAs and plasma sCD40L in DM patients with concomitant CKD.
After a placebo run–in period, the effects of simvastatin alone (S) or simvastatin + ezetimibe (S + E) were compared in a randomized, double–blind, cross–over study on platelet reactivity.
PLA formation and inflammatory parameters.
Eighteen DM patients with estimated glomerular filtration rate (eGFR) 15–59 mL/min × 1.73 m2 (CKD stages 3–4) (DM–CKD) and 21 DM patients with eGFR >75 mL/min (DM–only) were included.
PLAs were elevated at baseline in DM–CKD compared with DM–only (P = 0.04).
S + E reduced PLAs among total leukocytes and neutrophils in DM–CKD patients (P = 0.01 for both) but not in the DM–only group.
Platelet reactivity did not differ between patient groups or with LLT. Plasma levels of sCD40L (P < 0.001), elastase (P < 0.01) and von Willebrand factor (VWF) (P < 0.001) were elevated in DM–CKD compared with DM–only.
S + E reduced sCD40L in DM–CKD patients (P = 0.01), but LLT did not influence VWF or elastase.
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.